So, who is getting all those free drug samples, anyway? The poor, or the wealthy insured? A recent study puts this to the test.
Some refreshing candor – Novartis CEO Dan Vasella admits that he uses Lipitor (Pfizer‘s cholesterol drug) instead of Novartis’ Lescol. Medical responsibility triumphs over marketing spin!
Prasugrel, a promising Lilly/Daiichi Sankyo drug, is about to be submitted to the FDA. This will be an interesting one – the drug has blockbuster potential, but will it be fast-tracked – or side-tracked?
Very promising new Hepatitis B treatment may be on the horizon.
Breaking news from Chicago – two new filings. Takeda‘s DPP-4 inhibitor (Alogliptin, for diabetes) has now been filed for approval, as well as TAP‘s new GERD treatment.
Sciele gets approval for new formulations of its Sular HBP drug.
Mylan gets the OK to market a generic version of Zyrtec.
Who needs sleep? Just snort the latest sleep-replacement chemical!
BD gets the go-ahead for a rapid staph test, quickly identifying the presence of antibiotic-resistant strains.
The latest lawsuits for off-label promotion – Pfizer and Lipitor, Amgen and Enbrel.